Brain cancer trial tests double attack on recurrent tumors
NCT ID NCT04221503
Summary
This study is testing whether combining a pill called niraparib with a wearable device that delivers Tumor-Treating Fields (TTFields) can help control recurrent glioblastoma, a very aggressive brain cancer. The goal is to see if the device makes the tumor cells more vulnerable to the drug, potentially stopping or slowing their growth. The trial is for adults whose glioblastoma has returned after prior radiation treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.